Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
ALBT
Upturn stock ratingUpturn stock rating

Avalon GloboCare Corp. (ALBT)

Upturn stock ratingUpturn stock rating
$2.6
Last Close (24-hour delay)
Profit since last BUY0%
upturn advisory
Consider higher Upturn Star rating
BUY since 1 day
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

09/15/2025: ALBT (1-star) has a low Upturn Star Rating. Not recommended to BUY.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Analysis of Past Performance

Type Stock
Historic Profit -73.42%
Avg. Invested days 37
Today’s Advisory Consider higher Upturn Star rating
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 2.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 09/15/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 5.93M USD
Price to earnings Ratio -
1Y Target Price -
Price to earnings Ratio -
1Y Target Price -
Volume (30-day avg) -
Beta 0.02
52 Weeks Range 2.11 - 11.66
Updated Date 06/29/2025
52 Weeks Range 2.11 - 11.66
Updated Date 06/29/2025
Dividends yield (FY) -
Basic EPS (TTM) -8.01

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -243.34%

Management Effectiveness

Return on Assets (TTM) -23.8%
Return on Equity (TTM) -833.99%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 25157592
Price to Sales(TTM) 7.34
Enterprise Value 25157592
Price to Sales(TTM) 7.34
Enterprise Value to Revenue 18.38
Enterprise Value to EBITDA -4.45
Shares Outstanding 2132240
Shares Floating 1451691
Shares Outstanding 2132240
Shares Floating 1451691
Percent Insiders 23.35
Percent Institutions 0.83

ai summary icon Upturn AI SWOT

Avalon GloboCare Corp.

stock logo

Company Overview

overview logo History and Background

Avalon GloboCare Corp. is a biopharmaceutical company focused on developing and commercializing cell-based technologies and therapeutics. Founded to advance innovative healthcare solutions.

business area logo Core Business Areas

  • Cellular Immunotherapy: Developing allogeneic cell-based immunotherapies for cancer and other diseases.
  • Exosome Technology: Utilizing exosome technology for drug delivery and diagnostics.
  • Stem Cell Technology: Application of stem cell technologies to regenerative medicine and disease treatment.

leadership logo Leadership and Structure

The leadership team consists of experienced professionals in biopharmaceuticals, medicine, and business. The organizational structure is typical of a publicly traded biopharmaceutical company.

Top Products and Market Share

overview logo Key Offerings

  • AVA-011: A CAR-T therapy product candidate for B-cell acute lymphoblastic leukemia (B-ALL). Market share is currently developmental and not yet commercialized. Competitors include Novartis (Kymriah) and Gilead (Yescarta).
  • ACTEX(TM): ACTEX(TM) is an exosome-based diagnostic and therapeutic platform. Market share is in early stages. Competitors include Evox Therapeutics and Codiak BioSciences.

Market Dynamics

industry overview logo Industry Overview

The biopharmaceutical industry is characterized by high research and development costs, stringent regulatory requirements, and intense competition. Advancements in cell and gene therapies are driving growth.

Positioning

Avalon GloboCare is positioning itself as an innovator in cell-based immunotherapies and exosome technology. The company is competing with larger pharmaceutical companies and specialized biotech firms.

Total Addressable Market (TAM)

The total addressable market for cell and gene therapies is estimated to reach billions of dollars. Avalon GloboCare is positioned to capture a share of this market through its innovative technologies.

Upturn SWOT Analysis

Strengths

  • Innovative technology platform
  • Experienced management team
  • Focus on unmet medical needs
  • Proprietary technologies

Weaknesses

  • Limited financial resources
  • Early stage of development
  • Dependence on key personnel
  • High regulatory hurdles

Opportunities

  • Partnerships with larger pharmaceutical companies
  • Expansion into new therapeutic areas
  • Favorable regulatory changes
  • Increasing demand for personalized medicine

Threats

  • Competition from established pharmaceutical companies
  • Clinical trial failures
  • Changes in reimbursement policies
  • Intellectual property challenges

Competitors and Market Share

competitor logo Key Competitors

  • NVS
  • GILD
  • BMY
  • JNJ

Competitive Landscape

Avalon GloboCare faces intense competition from larger, more established pharmaceutical companies with greater resources. Its competitive advantage lies in its innovative technologies and focus on specific therapeutic areas.

Growth Trajectory and Initiatives

Historical Growth: Historical growth has been primarily through research and development and partnerships.

Future Projections: Future growth is dependent on successful clinical trials and commercialization of its product candidates. Analyst estimates vary widely.

Recent Initiatives: Recent initiatives include advancing clinical trials for AVA-011 and expanding its exosome technology platform.

Summary

Avalon GloboCare is an early-stage biopharmaceutical company with innovative technologies and a focus on unmet medical needs. The company faces significant challenges, including limited financial resources and competition from larger players. Successful clinical trials and partnerships are crucial for its future growth. Investors should closely monitor its financial performance and clinical trial progress.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company website
  • SEC filings
  • Third-party financial data providers (e.g., Yahoo Finance, Google Finance)

Disclaimers:

This analysis is for informational purposes only and should not be considered investment advice. The data is based on publicly available information and may not be entirely accurate or complete. Invest at your own risk.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Avalon GloboCare Corp.

Exchange NASDAQ
Headquaters Freehold, NJ, United States
IPO Launch date 2016-12-06
CEO, President & Director Dr. David K. Jin M.D., Ph.D.
Sector Real Estate
Industry Real Estate Services
Full time employees 4
Full time employees 4

Avalon GloboCare Corp., together with its subsidiaries, owns and operates commercial real estate properties in the United States. It also distributes the KetoAir device, which is a breathalyzer system that detects acetone levels in exhaled breath; and the AI Nutritionist software program that helps users monitor and manage ketogenic diet and related programs. Avalon GloboCare Corp. was founded in 2015 and is headquartered in Freehold, New Jersey.